The gardening intervention led to improvements in physical activity measures and other health outcomes in breast cancer survivors.
An update to guidelines from ASCO on the optimal management of patients with HER2+ breast cancer offers recommendations on timing and sequence of therapies.
Immune checkpoint inhibitors initiated soon before or after radiosurgery offer excellent outcomes in patients with brain metastases originating from melanoma.
The combination of an oncolytic virus with ipilimumab yielded a significantly higher response rate vs ipilimumab alone in patients with advanced melanoma.
Direct measurements of TRBV genes could provide a biomarker to predict response to dual HER2 blockade in women with HER2-positive breast cancer.
The inverse association with premenopausal breast cancer was seen across the entire distribution of BMI, and at a higher magnitude than previously reported.
A new study identified several metabolites and metabolic indicators as potential biomarkers for recurrence risk in non–muscle-invasive bladder cancer.
A large genomic analysis identified more than 60 new prostate cancer susceptibility loci, including one locus significantly associated with early onset.
An antigen-specific immunotherapeutic known as MAGE-A3 was no better than placebo for the adjuvant treatment of stage IIIB or IIIC melanoma.
In women with ovarian cancer, those with early life adversity and anxiety had more dysregulation of cortisol, suggesting they may be at risk for more negative outcomes.